Revenue
2022
2023
2024
2025
Xtl Biopharmaceuticals Ltd (XTLB)
Price$2.20Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2019
2020
2024
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $451,000 | $0 | $0 | — | — | — | — | — | — | — |
| Gross profit | $0 | $3,000 | $0 | $0 | — | — | — | — | — | — | — |
| Gross margin | — | 0.67% | — | — | — | — | — | — | — | — | — |
| Research & development | $28,000 | $98,000 | $31,000 | $30,000 | $30,000 | $38,000 | $35,000 | $38,000 | $43,000 | $443,000 | $578,000 |
| Operating expenses | $1.4M | $2.2M | $765,000 | $880,000 | — | — | — | — | — | — | — |
| Operating income | −$1.4M | −$2.2M | −$765,000 | −$880,000 | −$1.0M | −$948,000 | −$842,000 | −$793,000 | −$1.2M | −$2.6M | −$3.6M |
| Operating margin | — | −481.60% | — | — | — | — | — | — | — | — | — |
| EBITDA | −$752,000 | −$1.8M | −$1.8M | −$879,000 | −$1.0M | −$947,000 | — | — | −$1.2M | −$2.6M | −$3.6M |
| EBITDA margin | — | −400.89% | — | — | — | — | — | — | — | — | — |
| Net income | −$7.0M | −$1.0M | −$1.8M | −$1.3M | $435,000 | −$3.0M | −$763,000 | $3.6M | −$781,000 | −$2.5M | −$4.3M |
| Net profit margin | — | −227.72% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | — | -$0.00 | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | $0.01 | -$0.00 | -$0.01 | -$0.02 |
| Diluted EPSper diluted share | — | -$0.00 | -$0.00 | -$0.00 | $0.00 | -$0.01 | -$0.00 | $0.01 | -$0.00 | -$0.01 | -$0.02 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
RHUMBLINE ADVISERS | 6.23K |
GAMMA Investing LLC | 1.21K |
UBS Group AG | 125 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data